ADAMTS-4 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAMTS-4 (Aggrecanase-1, UniProt O75173) expressed in HEK293 cells. Used for aggrecan/COMP cleavage assays, inhibitor IC50 determinations, and antibody validation in cartilage and matrix remodeling research.
Expression system
HEK293
Cat. #
REC-ADAMTS4

In stock

SKU
REC-ADAMTS4
$498.00

Target Overview

ADAMTS-4 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 4; UniProt O75173) is a secreted zinc-dependent metalloprotease of the ADAMTS family. The full-length human sequence spans 837 amino acids and encompasses a signal peptide, prodomain, catalytic domain, disintegrin-like domain, thrombospondin type-1 repeat, cysteine-rich domain, and spacer domain. This recombinant is produced in HEK293 mammalian cells, which supports the glycosylation and folding patterns characteristic of the native secreted enzyme — relevant where activity against physiological substrates must be preserved. ADAMTS-4 is the principal aggrecanase responsible for cleavage at the Glu392–Ala393 bond within the interglobular domain of aggrecan, the predominant proteoglycan of articular cartilage. It also cleaves cartilage oligomeric matrix protein (COMP). Because both substrates are extracellular matrix (ECM) components, the recombinant is well suited for in-vitro substrate cleavage assays using purified aggrecan or COMP, as well as fluorogenic peptide substrates that mimic the Glu–Ala scissile bond. Researchers use this recombinant in several standard experimental formats: measuring enzyme kinetics (Km, kcat) against defined substrates; determining IC50 values for small-molecule or protein inhibitors such as TIMPs; generating defined aggrecan neoepitope fragments as positive controls in Western blot or ELISA; and as an antigen standard for antibody validation. Investigators validating the matched Triple Point Biologics anti-ADAMTS-4 antibody (SKU: RP-ADAMTS4) use this recombinant as a positive-control antigen in Western blot and immunohistochemistry workflows. The HEK293 expression system is preferred over bacterial platforms for this target because the multi-domain architecture of ADAMTS proteases requires eukaryotic folding machinery to yield catalytically active protein.

Background

ADAMTS-4 (Aggrecanase-1) is one of two primary aggrecanases — alongside ADAMTS-5 — that drive proteolytic degradation of aggrecan in the pericellular and extracellular matrix of articular cartilage. Cleavage at the canonical Glu392–Ala393 site within the aggrecan interglobular domain releases large glycosaminoglycan-bearing fragments from the collagen network, a step regarded as an early and rate-limiting event in cartilage matrix destruction. This biology has made ADAMTS-4 a widely studied research target in the context of osteoarthritis (OA) and rheumatoid arthritis, where loss of aggrecan from the articular surface is a defining pathological feature. In proteomic surveys of synovial fluid from knee OA patients, ADAMTS-4 and its aggrecan cleavage products recur as candidate biomarkers, as reflected in a 2026 systematic review and gene ontology analysis of synovial fluid proteomics (Parrotta EI et al., Cartilage, 2026; PMID 42129958). Recombinant ADAMTS-4 is used in such research to generate defined neoepitope standards and to calibrate ELISA or mass-spectrometry-based detection of cleavage products in biological fluids. Beyond cartilage, ADAMTS-4 has been detected in fibroblast populations in models of tissue fibrosis. A 2026 study using a preclinical model of pulmonary fibrosis resolution identified a persistent ADAMTS4-expressing alveolar fibroblast subpopulation, implicating the enzyme in ECM remodeling during fibrotic resolution (Zabihi M et al., Nat Commun, 2026; PMID 42103706). Such findings have expanded the use of recombinant ADAMTS-4 into fibrosis research, where it serves as an activity reference and immunostaining standard. In neurobiological contexts, ADAMTS-4 has been investigated for its activity on brain ECM components, including brevican and versican — aggrecan-family proteoglycans expressed in the central nervous system — with relevance to studies of neurodegeneration and perineuronal net remodeling. UniProt annotation also notes a potential role in the exacerbation of neurodegeneration in Alzheimer disease research, though the mechanistic basis remains an active area of investigation. ADAMTS-4 also cleaves COMP (cartilage oligomeric matrix protein), a pentameric ECM glycoprotein, which has opened substrate-specificity studies beyond the canonical aggrecan cleavage site. Researchers use the recombinant to characterise COMP fragmentation patterns and to compare substrate preference between ADAMTS-4 and ADAMTS-5 under defined assay conditions. Together, these research contexts — articular cartilage biology, fibrosis, neurodegeneration, and ECM remodeling — reflect the breadth of published applications for which active recombinant ADAMTS-4 is a necessary reagent.

Applications

  • Aggrecan substrate cleavage assay: detection of Glu392–Ala393 neoepitope by Western blot or ELISA
  • COMP (cartilage oligomeric matrix protein) cleavage and fragmentation analysis
  • Fluorogenic peptide substrate kinetics (Km, kcat determination) using Glu–Ala scissile-bond mimetics
  • Inhibitor IC50 determination for small molecules, TIMPs, or antibody-based inhibitors
  • Antibody validation positive control for anti-ADAMTS-4 antibody (RP-ADAMTS4) in Western blot and IHC
  • Synovial fluid or tissue lysate spiking as a defined antigen standard for proteomics or ELISA calibration
  • Comparison of substrate selectivity between ADAMTS-4 and ADAMTS-5 under matched assay conditions
  • Recombinant antigen for immunisation or competitive binding assays in antibody development workflows

References

  1. Vandendriessche A et al. Proteomic profiling of whole tissue sections in cardiac ATTR amyloidosis reveals increased extracellular matrix remodeling. Cardiovasc Pathol. 2026. doi:10.1016/j.carpath.2026.107838. PMID: 42303193.
  2. Zhao Y et al. Chromobox 3 assembles an epigenetic complex contributing to cystathionine γ-lyase-mediated protection against aortic aneurysm/dissection. Nat Commun. 2026. doi:10.1038/s41467-026-74048-2. PMID: 42236713.
  3. Yang X et al. Knockin expression of human ADAMTS5 impairs cardiovascular development and aggravates cerebral cavernous malformations in mice. Dis Model Mech. 2026. doi:10.1242/dmm.052668. PMID: 42144952.
  4. Parrotta EI et al. Synovial Fluid Proteomic Biomarkers in Knee Osteoarthritis: A Systematic Review and Gene Ontology Analysis. Cartilage. 2026. doi:10.1177/19476035261446251. PMID: 42129958.
  5. Zabihi M et al. Persistence of alveolar fibroblast-derived ADAMTS4+ cells in a preclinical model of delayed pulmonary fibrosis resolution. Nat Commun. 2026. doi:10.1038/s41467-026-72419-3. PMID: 42103706.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What molecular weight band should I expect for recombinant ADAMTS-4 on SDS-PAGE or Western blot?

The full-length human ADAMTS-4 sequence (837 aa, UniProt O75173) predicts a polypeptide backbone of ~93 kDa, but HEK293-derived recombinant typically migrates at 95–100 kDa under denaturing conditions due to N-linked glycosylation. After autocatalytic or furin-mediated prodomain removal, a processed catalytic form (~68 kDa) may also be present; examine your lot-specific SDS-PAGE gel image included with the Certificate of Analysis to confirm which form predominates in your aliquot. Purity is ≥90% by SDS-PAGE.

Which processing or isoform state is the recombinant ADAMTS-4 supplied in — full-length prodomain or processed active form?

This recombinant is produced in HEK293 cells and supplied as an active enzyme. HEK293 co-expresses furin-family proprotein convertases that typically cleave the ADAMTS-4 prodomain at the conserved RXXR motif, yielding a processed, catalytically competent form. The predominant species is therefore the furin-processed enzyme rather than the zymogen. Trace amounts of incompletely processed full-length protein can co-migrate at ~100 kDa. Refer to the CoA for the lot-specific band pattern; the catalytic domain alone is fully sufficient for standard aggrecanase activity assays.

What substrate does ADAMTS-4 cleave and how do I set up a fluorescent activity assay in vitro?

ADAMTS-4 is the principal aggrecanase cleaving aggrecan at the Glu392–Ala393 bond within the interglobular domain. For a quantitative fluorescent assay, use a FRET-based peptide substrate spanning that cleavage site (e.g., Mca-TEGE↓ARGSVI-Dnp) at 10–50 µM in assay buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 0.05% Brij-35. Start with 10–50 ng of recombinant ADAMTS-4 per 100 µL reaction at 37 °C, monitoring fluorescence at Ex/Em 320/405 nm. Purified aggrecan core protein or COMP can substitute for peptide substrates in gel-based cleavage assays.

What buffer conditions are optimal for ADAMTS-4 recombinant activity and are calcium or zinc supplements required?

ADAMTS-4 is a zinc-dependent metalloprotease that additionally requires calcium for full activity and structural stability. The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂ — is compatible with most activity assays and can be used directly. For diluted working stocks, supplement assay buffer with 5 mM CaCl₂. Avoid EDTA or EGTA chelators; these will inactivate the enzyme. Exogenous ZnCl₂ is not required and can be inhibitory above 0.1 mM. Optimal pH range is 7.0–8.0; activity drops sharply below pH 6.5.

What starting concentration of recombinant ADAMTS-4 should I use for an aggrecan cleavage assay and how do I determine linearity?

A reasonable starting point is 5–25 ng of ADAMTS-4 per reaction with 1–5 µg purified aggrecan substrate, incubated 2–16 hours at 37 °C. For FRET peptide assays, 10–20 ng/100 µL typically yields a linear rate over 30–60 minutes. To confirm you are in the linear range, run a time-course at two enzyme concentrations (e.g., 10 ng and 50 ng) and verify that doubling enzyme doubles signal. If running IC₅₀ inhibitor studies, establish the minimum enzyme concentration giving a robust S/B ratio (≥3:1) before titrating test compounds.

Can I use recombinant ADAMTS-4 as a Western blot positive control with the matched TPB antibody RP-ADAMTS4?

Yes — this is a primary use case for pairing REC-ADAMTS4 with RP-ADAMTS4. The rabbit polyclonal antibody (SKU: RP-ADAMTS4) is produced and validated in the same laboratory, so epitope compatibility is confirmed rather than assumed. Load 20–50 ng of recombinant per lane; the processed ~68 kDa and/or full-length ~95–100 kDa bands provide a clean, defined positive control. This is particularly useful when blotting low-expressing cell lysates where an endogenous ADAMTS-4 band may be ambiguous. See the RP-ADAMTS4 product page at /anti-adamts-4-rabbit-polyclonal-antibody for validated dilution ranges.

How much recombinant ADAMTS-4 should I load for Western blot to validate antibody RP-ADAMTS4 specificity?

For antibody specificity validation, 10–50 ng of REC-ADAMTS4 per lane is the recommended range. At 10 ng, a sensitive HRP-based detection system (e.g., ECL Plus, 1–5 min exposure) should yield a detectable band with minimal background. At 50 ng, the band is robust enough for stripped-membrane re-probing or multiplexed fluorescent detection. Run the recombinant alongside a cell lysate known to express ADAMTS-4 (e.g., IL-1β–stimulated chondrocyte or synoviocyte lysate) so band identity in the biological sample can be confirmed by co-migration with the defined molecular weight standard.

How should I store and handle recombinant ADAMTS-4 after receiving it to maintain activity?

Upon receipt, briefly centrifuge the vial, then aliquot into single-use volumes before freezing at −20 °C. Repeated freeze-thaw cycles cause measurable activity loss — even two cycles can reduce recoverable activity by 20–30% for metalloproteinases. Working dilutions should be prepared in storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol) or assay buffer supplemented with 0.1% BSA to reduce surface adsorption at low concentrations. Diluted stocks are stable for up to 8 hours on ice. For long-term storage beyond 6 months, keep at −80 °C.

Validation imagery coming soon

Western blot validation figures for REC-ADAMTS4 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →